


Enroquin™ Flavored Tablets (enrofloxacin)



Bioequivalence data: Enroquin Flavored Tablets vs. Pioneer

- Enroquin Flavored Tablets are indicated for the management of diseases associated with bacteria susceptible to enrofloxacin. Enroquin Flavored Tablets are indicated for use in dogs and cats.
- Therapeutically equivalent to the pioneer drug so you can expect the same safety and efficacy.
- Available in 22.7 mg tablets (100 and 500 count),
 68 mg tablets (50 and 250 count), and 136 mg tablets (50 and 200 count).



To order, please contact your Dechra or distributor representative or call (866) 683-0660. For more information, please visit www.dechra-us.com

Important Safety Information: As with all drugs, side effects may occur. In rare instances, use of this product in cats has been associated with Retinal Toxicity. Dosage should not exceed 5 mg/kg of body weight once daily in cats. Enrofloxacin is contraindicated in dogs and cats known to be hypersensitive to quinolones. The following adverse reactions have been reported: vomiting and diarrhea. In rare instances, anorexia, elevated liver enzymes, ataxia, seizures, depression, lethargy and nervousness have also been reported. Federal law prohibits the extralabel use of this drug in food-producing animals. Refer to the prescribing information for complete details or visit www.dechra-us.com.

24-hour Veterinary Technical Support available (866) 933-2472. Nonurgent Technical Support available via email support@dechra.com.

Enroquin™

Flavored Tablets (enrofloxacin)

CAUTION: Federal (USA) law restricts this drug to use by or on the order of a licensed

veterinarian.

→ Federal law prohibits the extralabel use of this drug in food-producing animals. ← DESCRIPTION: Enrofloxacin is a synthetic chemotherapeutic agent from the class of the quincione carboxylic acid derivatives. It has antibacterial activity against a broad spectrum of Gram negative and Gram positive bacteria (see Tables I and II). It is rapidly absorbed from the digestive tract, penetrating into all measured body tissues and fluids (See Table III). Tablets are available in three sizes (22.7, 68 and 136 mg enrofloxacin).

CHEMICAL CH₂CH NOMENCLATURE AND STRUCTURAL FORMULA: (4-ethyl 1-piperanzinyl)-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid СООН

ACTIONS: Microbiology: Quinolone carboxylic acid derivatives are classified as DNA gyrase inhibitors. The mechanism of action of these compounds is very complex and not yet fully understood. The site of action is bacterial gyrase, a synthesis promoting enzyme. The effect on Escherichia codi is the inhibition of DNA synthesis through prevention of DNA supercolling. Among other things, such compounds lead to the cessation of cell respiration and division. They may also interrupt bacterial membrane integrity. Enrofloxacin is bactericidal, with activity against both Gram negative and Gram positive bacteria. The minimum inhibitory concentrations (MICs) were determined for a series of 39 isolates representing 9 genera of bacteria from natural infections in dogs and cats, selected principally because of resistance to one or more of the following antibiotics: amplicillin, cephalothin, cotistin, chloramphenicol, erythromycin, gentamicin, kanamycin, penicillin, streptomycin, tetracycline, triple sulfa and sulfat/timethoprim. The MIC values for enrofloxacin against these isolates are presented in Table I. Most strains of these organisms were found to be susceptible to enrofloxacin in virito but the clinical significance has not been determined for some of the isolates. The susceptibility of organisms to enrofloxacin should be determined using enrofloxacin of enrofloxacin therapy. enrofloxacin therapy.

TABLE I - MIC Values for Enrofloxacin Against Canine and Feline Pathogens (Diagnostic laboratory isolates, 1984)				
Organisms	Isolates	MIC Range (mcg/mL)		
Bacteroides spp.	2	2		
Bordetella bronchiseptica	3	0.125-0.5		
Brucella canis	2	0.125-0.25		
Clostridium perfringens	1	0.5		
Escherichia coli	5*	<0.016-0.031		
Klebsiella spp.	11*	0.031-0.5		
Proteus mirabilis	6	0.062-0.125		
Pseudomonas aeruginosa	4	0.5-8		
Staphylococcus spp.	5	0.125		

*Includes feline isolate:

The inhibitory activity on 120 isolates of seven canine urinary pathogens was also investigated and is listed in Table II.

TABLE II - MIC Values for Enrofloxacin Against Canine Urinary Pathogens (Diagnostic laboratory isolates, 1985)			
Organisms	Isolates	MIC Range (mcg/mL)	
E. coli	30	0.06-2.0	
P. mirabilis	20	0.125-2.0	
K. pneumoniae	20	0.06-0.5	
P. aeruginosa	10	1.0-8.0	
Enterobacter spp.	10	0.06-1.0	
Staph. (coag. +)	20	0.125-0.5	
Strep. (alpha hemol.)	10	0.5-8.0	

Distribution in the Body: Enrofloxacin penetrates into all canine and feline tissues and body fluids. Concentrations of drug equal to or greater than the MIC for many pathogens (See Tables I, II and III) are reached in most tissues by two hours after dosing at 2.5 mg/kg and are maintained for 8-12 hours after dosing. Particularly high levels of enrofloxacin are found in urine. A summary of the body fluid/tissue drug levels at 2 to 12 hours after dosing at 2.5 mg/kg is

	sue distribution of l al Dose = 2.5 mg/k Post	g (1.13 mg/l		
	Canin	ie (n=2)	Feline	e (n=4)
Body Fluids (mcg/mL)	2 Hr.	8 Hr.	2 Hr.	12 Hr.
Bile	_	-	2.13	1.97
Cerebrospinal Fluid	_	-	0.37	0.10
Jrine	43.05	55.35	12.81	26.41
Eye Fluids	0.53	0.66	0.45	0.65
Whole Blood	1.01	0.36	-	
Plasma	0.67	0.33	-	_
Serum	_	-	0.48	0.18
Tissues (mcg/g) Hematopoietic	System			
iver	3.02	1.36	1.84	0.37
Spleen	1.45	0.85	1.33	0.52
Bone Marrow	2.10	1.22	1.68	0.64
ymph Node	1.32	0.91	0.49	0.21
Urogenital System				
Kidney	1.87	0.99	1.43	0.37
Bladder Wall	1.36	0.98	1.16	0.55
Testes	1.36	1.10	1.01	0.28
Prostate	1.36	2.20	1.88	0.55
Ovaries	-	-	0.78	0.56
Jterine Wall	1.59	0.29	0.81	1.05
Gastrointestinal and Cardiopulr	nonary Systems			
ung	1.34	0.82	0.91	0.33
Heart	1.88	0.78	0.84	0.32
Stomach	3.24	2.16	3.26	0.27
Small Intestine	2.10	1.11	2.72	0.40
arge Intestine	-	-	0.94	1.10
Other				
-at	0.52	0.40	0.24	0.11
Skin	0.66	0.48	0.46	0.17
Viuscle	1.62	0.77	0.53	0.29
Brain	0.25	0.24	0.22	0.12
Mammary Gland	0.45	0.21	0.36	0.30
Feces	1.65	9.97	0.37	4.18

Pharmacokinetics: In dogs, the absorption and elimination characteristics of the oral formulation are linear (plasma concentrations increase proportionally with dose) when enrofloxacin is administered at up to 11.5 mg/kg, twice daily.² Approximately 80% of the erally administered dose enters the systemic circulation unchanged. The eliminating organs, based on the drug's body clearance time, can readily remove the drug with no indication that the eliminating mechanisms are saturated. The primary route of excretion is via the urine. The absorption and elimination characteristics beyond this point are unknown. In cats, no oral absorption information is available at other than 2.5 mg/kg, administered orally as a single dose. Saturable absorption and/or elimination processes may occur at greater doses. When saturation of the absorption process occurs, the plasma concentration of the active moiety will be less than

predicted, based on the concept of dose proportionality.

Following an oral dose in dogs of 2.5 mg/kg (1.13 mg/lb), enrolloxacin reached 50% of its maximum serum concentration in 15 minutes and peak serum level was reached in one hour. The elimination half-life in dogs is approximately 2½-3 hours at that dose, while in cats it is greater than 4 hours. In a study comparing dogs and cats, the peak concentration were not different.

A graph indicating the mean serum levels following a dose of 2.5 mg/kg (1.13 mg/lb) in dogs (oral and intramuscular) and cats (oral) is shown in Figure 1




Figure 1: Serum Concentrations of Enrofloxacin Following a Single Oral or Intramuscular Dose at 2.5 mg/kg in Dogs and a Single Oral Dose at 2.5 mg/kg in Cats.

Breakpoint: Based on pharmacokinetic studies of enrofloxacin in dogs and cats after a single oral administration of 2.5 mg enrofloxacin/kg BW (i.e. half of the lowest-end single daily dose range for dogs and half the single daily dose for cats) and the data listed in Tables I and II, the following breakpoints are recommended for canine and feline isolates.

Zone Diameter (mm)	MIC (μg/mL)	Interpretation
<u>≥</u> 21	≤0.5	Susceptible (S)
18-20	1	Intermediate (I)
<17	>2	Resistant (R)

A report of "Susceptible" indicates that the pathogen is likely to be inhibited by generally achievable plasma levels. A report of "Intermediate" is a technical buffer and isolates falling into this category should be retested. Alternatively the organism may be successfully treated if the infection is in a body site where drug is physiologically concentrated. A report of "Resistant" indicates that the achievable drug concentrations are unlikely to be inhibitory and other therapy

Standardized procedures require the use of laboratory control organisms for both standardized disk diffusion assays and standardized dilution assays. The 5 μg enrofloxacin disk should give the following zone diameters and enrofloxacin powder should provide the following MIC values

QC strain		MIC (µg/mL)	Zone Diameter (mm)
E. coli	ATCC 25922	0.008-0.03	32-40
P. aeruginosa	ATCC 27853	1-4	15-19
S. aureus	ATCC 25923		27-31
S aurous	ΔTCC 20213	0.03-0.12	

INDICATIONS: Enroquin Flavored Tablets (enrofloxacin) are indicated for the management of ssociated with bacteria susceptible to enrofloxacin. Enroquin Flavored Tablets are or use in doos and cats.

EFFICACY CONFIRMATION: Dogs: Clinical efficacy was established in dermal infections (wounds and abossesse) associated with susceptible strains of Escherichia coli, Mebsiella pneumoniae, Proteus mirabilis, and Staphylococcus intermedius; respiratory infections (pneumonia, protilis, rimitabilis, and Staphylococcus intermedius; respiratory infections (pneumonia, protilis, rimitab) associated with susceptible strains of Escherichia coli and Staphylococcus aureus, and straphylococcus aureus. Cats: Clinical efficacy was established in demail infections (wounds and abossesse) associated with susceptible strains of Escherichia coli, Proteus mirabilis, and Staphylococcus aureus, and Staphylococcus epidermidis.

multocida, Staphylococcus aureus, and Staphylococcus epidermidis.

CONTRAINDICATIONS: Errolloxacin is contraindicated in dogs and cask known to be hypersensitive to quinolones. Dogs: Based on the studies discussed under the section on ANIMAL SAFETY SUMMARY, the use of enrolloxacin is contraindicated in small and medium breads of dogs during the rapid growth phase between 2 and 8 months of age). The safe use of enrolloxacin has not been established in large and giant breads during the rapid growth phase. Large breeds may be in this phase for up to one year of age and the giant breads for up to 18 months. In clinical field this utilizing a daily oral dose of 5.0 mg/kg, there were no reports of lameness or joint problems in any breed. However, controlled studies with histological evanipation of the activistic articlizes have not been conducted in the large or graint breeds

examination of the articular cartilage have not been conducted in the large or giant breeds.

ADVERSE REACTIONS: Dogs: Two of the 270 (0.7%) dogs treated with enrofloxacin at 5.0 mg/kg per day in the clinical field studies exhibited side effects, which were apparently drug-related. These two cases of vornition were self-limiting.

Post-Approval Experience: The following adverse experiences, although rare, are based on voluntary post-approval adverse drug experience reporting. The categories of reactions are listed in decreasing order of frequency by body system.

Gastrointestinal: anorexia, diarrhea, vomiting, elevated liver enzymes

castronnessma: anorexa, quarma, vomining, elevated liver enzymes Neurologic: ataxia, seizures Behavioral: depression, lethargy, nervousness Cats: No drug-related side effects were reported in 124 cats treated with enrofloxacin at 5.0 mg/kg per day for 10 days in clinical field studies. **Post-Approval Experience:** The following adverse experiences, although rare, are based on voluntary post-approval adverse experience reporting. The categories of reactions are listed in decreasing order of frequency by body system.

by body system.

Ocular: mydraissis, retinal degeneration (retinal atrophy, attenuated retinal vessels, and hyperreflective tapeta have been reported), loss of vision. Mydriasis may be an indication of impending or existing retinal changes.

Gastrointestinal: vomiting, anorexia, elevated liver enzymes, diarrhea

Neurologic: ataxia, seizures
Behavioral: depression, lethargy, vocalization, aggression

To report suspected adverse events, for technical assistance or to obtain a copy of the safety

To report suspected adverse events, for technical assistance or to obtain a copy of the safety data sheet (SDS), contact Dectire at (866) 933-2472. For additional information about adverse drug experience reporting for animal drugs, contact FDA at 1-888-FDA-VETS, or http://www.fda.gov/AnimaVeterinary/SafetyHealth ANIMAL SAFETY SUMMARY Dogs: Adult dogs receiving renriboxacin crally at a daily dosage rate of 52 mg/kg for 13 weeks had only isolated incidences of vomition and inappetence. Adult dogs receiving the tablet formulation for 30 consecutive days at a daily freatment of 25 mg/kg did not histological parameters. Daily doses of 125 mg/kg for up to 11 days induced vomition, inappetence, depression, difficult locomotion and death while adult dogs receiving 50 mg/kg/day for 14 days had clinical signs of vomition and inappetence.
Adult dogs dosed intramuscularly for three treatments at 12.5 mg/kg dail to 25 mg/kg did not exhibit lether significant clinical signs or effects upon the clinical chemistry, hematological parameters. Oral treatments at 12.5 mg/kg. at 12 hour intervals, did not exhibit either significant clinical signs or effects upon the clinical chemistry, hematological or histological parameters. Oral treatment of 15 to 28 week old growing puppies with daily dosage rates of 25 mg/kg has induced abnormal carriage of the carpal joint and weakness in the hindquarters. Significant

has induced abnormal carriage of the carpal joint and weakness in the hindquarters. Significant improvement of clinical signs is observed following drug withdrawal. Microscopic studies have identified lesions of the articular cardiage following 30 day treatments at either 5, 1 or 25 mg/kg in this age group. Clinical signs of difficult ambulation or associated cardiage lesions have not been observed in 29 to 34 week old puppies following daily treatments of 25 mg/kg for 30 consecutive days nor in 2 week old puppies with the same treatment schedule. Tests indicated no effect on circulating microfilariae or adult heartworms (*Dirofilaria immitis*). when dogs were treated at a daily dosage rate of 15 mg/kg for 30 days. No effect on

Non-drops where traced are days observed.

No adverse effects were observed on reproductive parameters when male dogs received 10 consecutive daily treatments of 15 mg/kg/day at 3 intervals (90, 45 and 14 days) prior to

breeding or when female dogs received 10 consecutive daily treatments of 15 mg/kg/day at precenting of when terms a cogs received in 1 consecutive daily treatments or 1s migrigory at 4 intervals: between 30 and 0 days prior to breeding, early pregnancy between 10th & 30th days), late pregnancy (between 40th & 60th days), and during lactation (the first 28 days). Cats: Cats in age ranges of 3 to 4 months and 7 in 10 months received daily treatments of 25 mykg for 30 consecutive days with no adverse effects upon the clinical chemistry, hematological or histological parameters. In cats 7-10 months of age treated daily for 30 consecutive days, 2 of 4 receiving 5 mg/kg, 3 of 4 receiving 15 mg/kg, 2 of 4 receiving 25 mg/kg and 1 of 4 nontreated controls experienced occasional womition. Five to 7 month old cats had no side effects with digital treatments of 15 mg/kg or 90 days but 2 of 4 receiving 15 mg/kg and 10 days. effects with daily treatments of 15 mg/kg for 30 days, but 2 of 4 animals had articular cartilage lesions when administered 25 mg/kg per day for 30 days.

Doses of 125 mg/kg for 5 consecutive days to adult cats induced vomition, depression,

incoordination and death while those receiving 50 mg/kg for 6 days had clinical signs of vomition, inappetence, incoordination and convulsions, but they returned to normal. Errofloxacin was administered to thirty-two (8 per group), six-to eight-month-old cats at doses of 0, 5, 20, and 50 mg/kg of body weight once a day for 21 consecutive days. There were no adverse effects observed in casts that received 5 mg/kg body weight of enrofloxacin. The administration of enrofloxacin at 20 mg/kg body weight or greater caused salivation, vomition, and depression. Additionally, dosing at 20 mg/kg body weight or greater resulted in mild to severe fundic lesions on ophthalmologic examination (change in color of the fundus, central or generalized retinal degeneration), abnormal electroretinograms (including blindness), and diffuse light microscopic changes in the retina.

DRUG INTERACTIONS: Compounds that contain metal cations (e.g., aluminum, calcium, iron,

magnesium) may reduce the absorption of some quinolone-class drugs from the intestinal tract. Concomitant therapy with other drugs that are metabolized in the liver may reduce the clearance rates of the quinolone and the other drug. **Dogs:** Enrofloxacin has been administered to dogs at a daily dosage rate of 10 mg/kg concurrently with a wide variety of other health products including antibulinities (praziquantel, lebantel, sodium disophenol), insecticides (tentificin, pyrethrins), heartworn preventatives (delity/cathemazine) and other antibiotics (ampicillin, gentamicin sulfate, penicillin, dhydrostreptomycin). No incompatibilities with other drugs are known at this time.

Cats: Enrollosion was administered at a daily dosage rate of 5 mg/kg concurrently with antheimitics (praziquantel, febantel), an insecticide (proposur) and another antibacterial (ampicilin). No incompatibilities with other drugs are known at this time. WARNINGS: For use in animals only. In rare instances, use of this product in cats has been associated with Retinal Toxicity. Do not exceed 5 mg/kg of body weight per day in cats. Safety in breeding or pregnant cats has not been established. Keep out of reach of children.

established. Keep out of reach of children.

Avoid contact with eyes in case of contact, immediately flush eyes with copious amounts of water for 15 minutes. In case of dermal contact, wash skin with soap and water. Consult a physiciant if intitation persists following ocular or dermal exposure. Individuals with a history of hypersensitivity to quinolones should avoid this product. In humans, there is a risk of user photosensitization within a few hours after excessive exposure to quinolones. If excessive accidental exposure occurs, avoid direct sunlight.

For customer service or to obtain product information, including Safety Data Sheet, call Dechra

PRECAUTIONS: Quinolone-class drugs should be used with caution in animals with known or suspected Central Nervous System (CNS) disorders. In such animals, quinolones have, in rare instances, been associated with CNS stimulation which may lead to consulsive seizure. Quinolone-class drugs have been associated with cartilage erosions in weight-bearing joints and other forms of arthropathy in immature animals of various species.

The use of fluoroquinolones in cats has been reported to adversely affect the retina. Such

DOSAGE AND ADMINISTRATION: Dogs: Administer orally at a rate to provide 5-20 mg/kg (2.27 to 9.07 mg/lb) of body weight. Selection of a dose within the range should be based on clinical experience, the severity of disease, and susceptibility of the gathogen. Animals which receive doses in the upper-end of the dose range should be carefully monitored for clinical signs that may include inappetence, depression, and vornition. If dogs do not consume Enroquin Flavored Tablets willingly when offered by hand, then alternatively the tablet(s) may be offered in the food or hand-administered (pilled) as with other oral tablet medications.

Weight of	Weight of Once Dail				
Dog	5.0 mg/kg	10.0 mg/kg	15.0 mg/kg	20.0 mg/kg	
9.1 kg	2 x 22.7 mg	1 x 22.7 mg plus	1 x 136 mg	1 x 136 mg plus	
(20 lb)	tablets	1 x 68 mg tablets	tablet	2 x 22.7 mg tablets	
27.2 kg	1 x 136 mg	2 x 136 mg	3 x 136 mg	4 x 136 mg tablets	
(60 lb)	tablet	tablets	tablets		

All tablet sizes are double scored for accurate dosing.

Cats: Administer orally at 5 mg/kg (2.27 mg/lb) of body weight. The dose for dogs and cats may be administered either as a single daily dose or divided into two (2) equal daily doses administered at twelve (12) hour intervals. The dose should be continued for at least 2.3 days beyond cessation of clinical signs, to a maximum of 30 days. In cats, Enroquin Flavored Tablets should be pilled. After administration, watch the animal closely to be certain the entire dose has been consumed.

Weight of Cat	Once Daily Dosing Chart (5 mg/kg/day)
5 lb (2.27 kg)	1/2 x 22.7 mg tablet
10 lb (4.5 kg)	1 x 22.7 mg tablet
15 lb (6.8 kg)	1 and 1/2 x 22.7 mg tablets or 1/2 x 68 mg tablet

All tablet sizes are double scored for accurate dosing.

Dogs & Cats: The duration of treatment should be selected based on clinical evidence. Generally, administration of Enroquin Flavored Tablets should continue for at least 2-3 days beyond cessation of clinical signs. For severe and/or complicated infections, more prolonged therapy, up to 30 days, may be required. If no improvement is seen within five days, the diagnosis should be reevaluated and a different course of therapy considered.

revariated and a dimeter locuse of underpy consulence. The lower limit of the dose range in dogs and the daily dose for cats was based on efficacy studies in dogs and cats where enrofloxacin was administered at 2.5 mg/kg twice daily. Target animal safety and toxicology were used to establish the upper limit of the dose range for dogs

and treatment duration for dogs and cats.

STORAGE: Dispense tablets in tight containers only ed room temperature, 68-77°F (20-25°C).

Flavored Tablets NDC Number	Tablet Size	Tablets/Bottle
17033-302-10	22.7 mg	100 Double Scored
17033-302-50	22.7 mg	500 Double Scored
17033-306-05	68 mg	50 Double Scored
17033-306-25	68 mg	250 Double Scored
17033-313-05	136 mg	50 Double Scored
17033-313-20	136 mg	200 Double Scored

ANADA 200-551, Approved by FDA

REFERENCES:

Doughherty, T.J., & Saukkonen, J.J. (1985). Membrane permeability changes associated with DNA gyrase inhibitors in *Escherichia Coli*. Antimicrob Agents Chemother, 28 (2), 200-206. Walker, R.D., Stein, G.E., Hauptmam, J.G., McDonald, K.H. (1992). Pharmacokinetic evaluation of enrofloxacin administered orally to healthy dogs. Am J Vet Res, 53 (12): 2315-2319.

Manufactured for:

Dechra Veterinary Products 7015 College Boulevard, Suite 525 Overland Park, KS 66211 USA

Neutral Code No.: UK/DRUGS/58/UA/2007 Rev. September 2017

